Application of 403-33-8In 2021 ,《Optimization of a Series of RIPK2 PROTACs》 appeared in Journal of Medicinal Chemistry. The author of the article were Miah, Afjal H.; Smith, Ian E. D.; Rackham, Mark; Mares, Alina; Thawani, Aditya R.; Nagilla, Rakesh; Haile, Pamela A.; Votta, Bartholomew J.; Gordon, Laurie J.; Watt, Gillian; Denyer, Jane; Fisher, Don T.; Dace, Phoebe; Giffen, Paul; Goncalves, Andrea; Churcher, Ian; Scott-Stevens, Paul; Harling, John D.. The article conveys some information:
Receptor-interacting serine/threonine protein kinase 2 (RIPK2) is an important kinase of the innate immune system. Herein, we describe the optimization of a series of RIPK2 PROTACs which recruit members of the inhibitor of apoptosis (IAP) family of E3 ligases. Our PROTAC optimization strategy focused on reducing the lipophilicity of the early lead which resulted in the identification of analogs with improved solubility and increased human and rat microsomal stability. We identified a range of IAP binders that were successfully incorporated into potent RIPK2 PROTACs with attractive pharmacokinetic profiles. Compound 20 possessed the best overall profile with good solubility, potent degradation of RIPK2, and associated inhibition of TNFα release. A proof-of-concept study utilizing a slow release matrix demonstrated the feasibility of a long-acting parenteral formulation with >1 mo duration. This represents an attractive alternative dosing paradigm to oral delivery, especially for chronic diseases where compliance can be challenging. In the experiment, the researchers used many compounds, for example, Methyl 4-fluorobenzoate(cas: 403-33-8Application of 403-33-8)
Methyl 4-fluorobenzoate(cas: 403-33-8) can be used in the synthesis of trisubstituted imidazole derivatives containing a 4-fluorophenyl group, a pyrimidine ring, and a CN- or CONH2-substituted benzyl moiety.Application of 403-33-8
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics